On April 29, 2025, the "Hangzhou Taikun Biopharmaceutical Industry and Finance Summit," jointly organized by Tailong Venture Capital, Tigermed, Hangzhou Industrial Investment Group, and Binjiang Financial Investment Group, was successfully held at the Kaiyuan Mingdu Hotel in Binjiang District, Hangzhou. Jack Wang, Chairman of Hong Kong WinHealth Pharma Group, attended the conference. Meanwhile, WinHealth Pharma also participated as a featured exhibitor.
The summit aimed to promote an in-depth understanding of the biopharmaceutical industry ecosystem and relevant policies in Hangzhou among various sectors, as well as to enhance communication and cooperation among investment institutions. The conference focused on in-depth discussions on cutting-edge technologies in the biopharmaceutical field, industry policies and trends, business development and international expansion, as well as opportunities in AI and industry-finance collaboration. It attracted numerous academicians, experts, industry leaders, top investment banks, and representatives from the Taikun Fund ecosystem to come together.
As a comprehensive, fully-integrated biopharmaceutical company, WinHealth Pharma has always focused on the production, development, and commercialization of innovative drugs, with a commitment to continuously providing more accessible healthcare solutions to patients. At the summit, WinHealth Pharma showcased its core competencies in innovation strategy, global strategic collaboration networks, and product porfolios, attracting many industry professionals to engage in discussions.
This event not only served as a key platform for WinHealth Pharma to demonstrate its brand strength but also marked a critical step in connecting industry resources and exploring collaboration opportunities. Moving forward, the company will continue to strengthen its core competencies, optimize its industry positioning, and collaborate with industry peers to build Hangzhou as a hub for the biopharmaceutical industry, driving the high-quality development of China’s biopharmaceutical sector.
About WinHealth Pharma
Founded in 2006, WinHealth Pharma is a Hong Kong-headquartered biopharmaceutical company with a comprehensive, end-to-end value chain. The company focuses on three core areas: proprietary pharmaceutical products, CSO business, and specialty care, with a strong commitment to the development and commercialization of cutting-edge medicines. Guided by a patient-first philosophy, we are dedicated to delivering breakthrough therapies and innovative healthcare solutions to patients with cardio-renal diseases, hematologic cancers, gastrointestinal diseases, respiratory and infectious diseases, rare diseases, and other unmet medical needs. Our commitment is to improve patients’ lives through transformative treatments. With a well-established presence in China, WinHealth Pharma is actively expanding across Asia and other international markets, building a comprehensive healthcare ecosystem, driving innovation, and addressing the evolving treatment needs of patients. For more information, please visit www.winhealth.hk.